Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

29/12/25 - by

“It all started when I was 58. I didn’t have any symptoms – apart from needing to go to the toilet a lot.

At night, I was trying to pee, couldn’t, then went back to bed and the next minute needed to get up again. And I thought, ‘well, this is a bit odd’, so I went to the doctors. 

There’s no national screening for prostate cancer, but you can have a blood test that measures your Prostate-Specific Antigen (PSA) that can be an indicator of prostate problems. I was tested, then got the phone call from my doctor that nobody wants - my GP said, ‘We need to see you now’, as in the following day after the test.

My PSA was 649 – a normal reading would have been 4 for a man of my age.

Everything happened very quickly after that and within a couple of weeks I had a biopsy followed by scans.

I was diagnosed at stage 4 – the cancer had spread to my lymph nodes and sternum. I was told I had a 25 per cent chance of living five more years. My reaction? I thought I’d better make the most my life while I still could.

Then my consultant specialist asked me whether she could put me forward for this drug trial and I thought, ‘Well, why the hell not?’  - because it was obvious that it was really bad.

“My family and I are so grateful”

Looking back now, I can see that I was very lucky to go on the STAMPEDE trial because it saved my life. I had a very high PSA, and the cancer had already moved around my body. It was my first realisation that as I was of mixed race (half African / British) I was at much greater risk of contracting prostate cancer.

As part of the trial I was treated with abiraterone and Zoladex, which both reduce testosterone. Within a very short period, my PSA had dropped from 649 to less than 1, where it stayed for some years, enabling me to carry on working a fairly physical job and conduct a normal family life - that's how good that combination of drugs was. My family and I are so grateful and I hope the trial has been helpful to subsequent patients.”

My diagnosis was a shock, but within a day or two I just thought, ‘Well, I don’t feel any different’, and I just got on with it as if nothing was happening.

I’m a domestic appliance engineer and it’s quite a physical job because you're lifting heavy machines around all the time. But it didn't affect me at all. The year after I was diagnosed, I launched my own business, and I did what I had to do to get it off the ground.

I did have moments of slight depression very early on, but it quite quickly dissipated. And I did get side-effects from the treatment – tiredness for one – but I managed to set them aside. My family and I were still going on decent holidays. I'm a bit of a petrolhead, so I was still riding my bikes and messing about with cars.

Chris sits in a relaxed pose in woodland

 

“I’m thankful the treatment worked”

I know people are worried about me. My wife said she didn’t think I had come to terms with the fact that I had cancer. But I said, “I’m not going to sit in the corner and quiver. That's not me, is it?”

The way I see it, I’m living my life despite my cancer diagnosis. The doctor told me that I must have had it for many years without any real symptoms.

The treatment worked - I was thankful for that - and I carried on working right up till the day, in 2022, when my PSA started to rise again to 3.4.

At that point, I was taken off abiraterone. I figured I’d had a good run on it and I’d already been taken off Zolodex a few years before. We were discussing what my next treatment would be when I was diagnosed with leukaemia - which complicated things a bit!

I had to have a blood transfusion and then in March 2023, a stem cell transplant from my son – I was so grateful that he could do that for me. But I was in hospital for weeks after that, and in a bad way. By that stage, my wife and I had decided to part ways, and my divorce was finalised while I was still in my hospital bed.

After my treatment for leukaemia, which appears to have been successful, I was able to have treatment for my prostate cancer again.

“People who meet me can’t believe I’ve faced cancer twice”

In October 2023, it was confirmed that the prostate cancer had got worse, and I had twenty rounds of radiotherapy on a daily basis, for five weeks.

In January 2025, a body scan showed that the cancer had progressed again in my lymph nodes. I was treated with ten rounds of chemotherapy – and my latest scan was normal. When people meet me, they say they can’t believe I’m 70, let alone having faced two cancer diagnoses. Through the treatment I’ve lost my eyebrows, eyelashes, and underarm hair, but I’ve managed to keep what was on my head!

I’m keeping strong as well. I've taken up walking, and the furthest I've walked so far is 15.2 miles in a day. I love travelling and I’ve got a few trips planned later this year in my caravan.

I live on a caravan site currently and I do odd jobs for people on the site so that keeps my mind ticking over too.

Chris wearing a hat and sunglasses smiles for the camera

 

“Find that positivity – it’s a light bulb of hope”

Now I notice men who need to go to the toilet a lot and I speak to them, to try and get them to get tested at every opportunity I can. Maybe I talk about it too much, but I will carry on because we've all got men within our family and friends, and that one conversation that might save someone's life makes it worthwhile.

I know we’re all different and that treatment affects us all in many ways, but it’s important to get your own head right if you can. I understand, I’ve grown up in difficult times, in a difficult family, and it has helped me to try and find that positivity. You’ve got it in there, and once you start nurturing it a little, you start feeling the benefits - it's a light bulb of hope.

Most importantly, you, family, and friends need to make sure that any man within your circle is aware that cancer can be a silent killer, quite often with no symptoms. Getting tested is, in my view, the best way to try and safeguard your future.